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Little evidence-based guidance is available to aid clinicians in determining short-term
prognoses in very severe COPD patients. Therefore, the present study was designed to
provide a prospective assessment (1) of the mortality rates and (2) whether the baseline
measurements may be determinants of 1-year mortality in hypoxemic COPD patients
receiving long-term oxygen therapy (LTOT).
Seventy-eight clinically stable patients with advanced COPD treated using LTOT were
enrolled in a prospective cohort study. Outcome variable: ﬁrst-year mortality. Baseline
measurements: categorical variables: age (o60 or X60 years); gender; body mass index
(o20 or X20 kg/m2); fat-free mass (FFM) index (o16 [men] and o15 kg/m2 [women];
baseline dyspnea index (BDI) (p3 or 43); and corticosteroid use. Continuous variables:
smoking history; lung function; FFM; fat mass; hemoglobin; hematocrit; arterial blood
gases; forearm muscle strength; St. George’s Respiratory Questionnaire (SGRQ); and
comorbidity score. By the end of 1-year of follow-up, 12 patients (15.4%) had died.
Kaplan–Meier curves showed that BDIp3 was the only variable associated with higher
mortality. Cox proportional hazards analysis revealed that lower PaO2 and SpO2, higher
PaCO2 and SGRQ scores were associated with reduced survival. In the multivariate analysis,Elsevier Ltd. All rights reserved.
Rodrigues, 6-45. Ap. 133, Vila Cidade Universita´ria, Bauru, SP, CEP 17012-535, Brazil.
+55 14 3882 2238.
hoo.com.br (K.D. Coleta), liciana@ibb.unesp.br (L.V.A. Silveira), dan_lima2003@yahoo.com.br
E.A. Rampinelli), degodoy@fmb.unesp.br (I. Godoy), irma@fmb.unesp.br (I. Godoy).
ARTICLE IN PRESS
First-year survival in COPD 513BDI remained predictive of mortality (hazard ratio [HR], 0.50; 95% conﬁdence interval [CI],
0.31–0.81), as did PaO2 (HR, 0.49; 95% CI, 0.26–0.95).
These data suggest that readily available parameters as dyspnea intensity and hypoxemia
severity may be useful in predicting ﬁrst-year survival rates in advanced COPD patients
receiving LTOT.
& 2007 Elsevier Ltd. All rights reserved.Introduction
COPD is currently the fourth leading cause of death in the
world, and further increases in the prevalence and mortality
of the disease have been predicted for the coming decades.1
Studies indicate that approximately 10% of the adult popula-
tion in Europe, 13.9% in the USA and 15.8% in Brazil has COPD
and 0.2–1.4% can be deﬁned as having severe disease.2–4
COPD is a progressive disease that often leads to
respiratory failure. Long-term oxygen therapy (LTOT) is the
single treatment that has proven effective in increasing
survival in patients with chronic hypoxemia.5,6 Neverthe-
less, the 1-year survival rate in severely hypoxemic COPD
patients receiving LTOT is poor, ranging from 70% to
82.8%,7–10 albeit decidedly better than the 5-year survival
rate, which ranges from 19.1% to 41.5%.7,9,10
Mortality in patients with severe COPD has been asso-
ciated with age,8,9,11 gender,12 airﬂow obstruction,8,13
malnutrition,10,14,15 concomitant malignancy,10,16 smoking
habits,16 hypoxemia16 and exercise tolerance.11 However,
there is little evidence-based guidance to aid clinicians in
determining short-term prognoses for patients with ad-
vanced COPD.17 We hypothesized that predictors of ﬁrst-
year survival in hypoxemic COPD patients might be different
from those previously described for long-term survival.
Therefore, the present study was designed to provide a
prospective assessment (1) of the mortality rates and (2) the
baseline measurements that may be determinants of
mortality after 1-year of follow up in hypoxemic COPD
patients admitted to a LTOT program.Methods
Patients
We conducted a prospective cohort study of patients with
COPD enrolled in the LTOT program of a tertiary-care
university hospital (Botucatu Medical School, Botucatu,
Brazil). Between October 2003 and December 2005, a total
of 131 patients initiated LTOT. The initial selection consisted
of patients who met the criteria set forth in the Global
Initiative for Chronic Obstructive Lung Disease (GOLD) and
by the Brazilian Thoracic Society (BTS) for COPD diagnosis
(postbronchodilator forced expiratory volume (FEV1)/forced
vital capacity (FVC) ratio of less than 0.70) and for LTOT.1,18
Additional inclusion criteria were as follows: (1) clinically
stable condition (i.e., no changes in medication dosage or
frequency and no exacerbations of disease or hospital
admissions in the preceding 6 weeks); and (2) use of LTOT
for at least 3 months (to avoid inclusion of patients with
temporary oxygen supplementation).A total of 53 patients were excluded from the follow-up.
In 47 patients the primary diagnosis was not COPD:
restrictive lung disorder (n ¼ 14), vascular pulmonary
disease (n ¼ 9), bronchiectasis (n ¼ 6), respiratory sleep
disorders (n ¼ 5) and miscellaneous diagnoses (n ¼ 13). Five
patients did not perform spirometry and therefore did not
comply with the previously described COPD diagnosis
criteria. Only one patient with conﬁrmed COPD diagnosis
was unavailable for follow-up. Therefore, the ﬁnal sample
consisted of 78 COPD patients.
All patients were optimized in terms of standard medical
therapy according to the GOLD and BTS guidelines.1,18
Participants were aware of the proposed study procedures
and freely gave written informed consent. All procedures
were approved by the Research Ethics Committee of the
Botucatu Medical School University Hospital.
Design
Data related to the following were collected at baseline:
gender; age; smoking history; body composition variables;
dyspnea sensation; spirometry; arterial blood gases; chest
X-ray; electrocardiogram; forearm muscle strength; health
status; and comorbid conditions. All patients were evalu-
ated every 3 months in order to assess LTOT compliance,
determine the occurrence of exacerbations/hospitalizations
and adjust the oxygen ﬂow if necessary. They were followed
for at least 1 year or until death. For patients who missed a
follow-up appointment, data on patient survival were
obtained by telephone interview with the family. Basic
causes of death were reviewed on the death certiﬁcates
when available.
Methods
Smoking history was determined based on the number of
pack-years. Lung function and reversibility tests were
performed using the Med-Graph 1070 spirometer (Medical
Graphics Corporation; St. Paul, MN, USA), according to the
criteria set by the American Thoracic Society.19 Values of
FEV1 are expressed in liters, in percentages of FVC and as
percentages of reference values.20 For PaO2 and PaCO2
measurements (kPa), arterial blood was drawn from the
radial artery under standard anaerobic conditions, while the
patient was at rest and breathing room air (Stat Proﬁle 5
Plus; Nova Biomedical; Waltham, MA, USA). Peripheral
oxygen saturation (SpO2) was assessed using a portable
Onyx oxymeter (Model 9500 Oximeter; Nonin Medical Inc.;
Minneapolis, MN, USA).
Body weight and height were measured. Body mass index
(BMI ¼ weight in kg/height in m2) was calculated. Body
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analyzer (BIA 101A; RJL systems; Detroit, MI, USA).
Resistance was measured on the right side of the body with
the patient in the supine position, in accordance with the
ESPEN guidelines.21 Fat-free mass (FFM) was estimated (in
kg) using a group-speciﬁc regression equation developed by
Schols et al.22 and the FFM index (FFMI) was also calculated
(expressed as FFM/height2). Fat mass (FM) was calculated as
total body weight minus FFM. Forearm muscle strength was
estimated based on handgrip strength (HGS) of the dominant
hand, as measured using a dynamometer (TEC-60; Technical
Products; Clifton, NJ, USA).
Comorbidity was quantiﬁed according to the index
devised by Charlson et al.23 and designated the Charlson
comorbidity index (CCI). This index was designed to predict
the impact that comorbidity has on prognosis in patients
with chronic diseases. It assigns each disease a score of 1–6,
which is proportional to the disease-related risk of death.
Myocardial infarction, congestive heart failure, peripheral
vascular disease, cerebrovascular disease, dementia, COPD,
connective tissue disease, peptic ulcer disease, mild liver
disease and diabetes are assigned a score of 1. A score of 2 is
assigned to diabetes with end-organ damage, hemiplegia,
renal disease and malignancies, including leukemia and
lymphoma. A score of 3 is assigned to moderate or severe
liver disease, whereas AIDS and metastatic malignancies are
assigned a score of 6.
A translated version of the St. George’s Respiratory
Questionnaire (SGRQ), validated for use in Brazil, was used
to evaluate patient health-related quality of life (QoL).24 A
similarly Brazilian modiﬁed version of the baseline dyspnea
index (BDI), developed by Mahler et al.,25,26 was used to
determine the degree of dyspnea. The BDI incorporates
information related to the individual components of dyspnea
(functional impairment, as well as the magnitude of the task
and the amount of effort required to induce dyspnea). The
total BDI score ranges from 0 to 12, higher values
representing better function.
Oxygen treatment
Oxygen therapy was prescribed for at least 18 h/day, using
nasal prongs. The ﬂow rate necessary to obtain an SpO2
X90% was determined in the LTOT clinic. The oxygen was
delivered from an oxygen concentrator in most patients and
from cylinders in a few cases. The patients and their families
were instructed in the use of the oxygen delivery system.
The oxygen equipment was provided by the supplier, which
also provided in-home technical service to patients. The
LTOT compliance data were evaluated by self-reporting
obtained from patients and their caregivers and character-
ized as appropriated by the investigator if the use reported
was in compliance with the prescription.
Statistical analysis
All data were analysed using the SAS statistical package
(version 9.1.3; SAS Institute Inc., Cary, NC, USA). Means and
standard deviations are reported for baseline character-
istics. Assessment of baseline homogeneity between survi-
vors and deceased patients was performed using theunpaired t-test for continuous variables or the Mann–Whit-
ney test for ordinal variables.
Patients were categorized by age (o60 or X60 years),
gender (0 ¼ male; 1 ¼ female) and BDI (p3 or 43). The
cut-off for BDI was the lowest quartile (0 to 25th
percentile). Corticosteroid use was deﬁned as receiving oral
corticosteroids for 43 months during the previous year
(0 ¼ no; 1 ¼ yes). Patients were stratiﬁed into two cate-
gories according to the following variables: BMI (o20 or
X20 kg/m2),10,14 and FFMI (o16 kg/m2 [for men] and
o15 kg/m2 [for women] or X16 kg/m2 [for men] and
X15 kg/m2 [for women]).27
Kaplan–Meier survival curves were created to display
differences in survival by selected risk factors: age, gender,
oral corticosteroid use, BMI, FFMI and BDI. The differences
between survival curves were assessed using the log rank
test. The univariate analysis was based on the Cox
proportional hazards models using each of the potential
predictors of survival as independent variables and survival
status as the dependent variable. For each continuous
variable, the Cox proportional hazards models was adjusted
for smoking history, FVC, FEV1, FEV1/FVC, hemoglobin,
hematocrit, PaO2, PaCO2, SpO2, FFM, FM, HGS, CCI and SGRQ
score (symptom, activity, impact and total score).
Independent variables associated with mortality (pre-
senting a po0.20) in the univariate analysis were then
incorporated into a forward stepwise multivariate analysis
likewise based on the Cox proportional model. Prior to the
multivariate analysis, confounding factors were evaluated,
as were the interactive effects between variables, as well as
their possible colinearity.
In all analyses, values of po0.05 were considered
statistically signiﬁcant.Results
Clinical characteristics
From a total of 131 patients initiating LTOT during the study
period, 78 (43 males and 35 females) were included in the
study. The mean age was 66.078.9 years. Baseline
characteristics of the 78 COPD patients, together with 1-
year survival data, are shown in Table 1. As expected, the
majority of the patients included presented severe airﬂow
obstruction, severe hypoxemia and mild hypercapnia.
Pharmacological treatment included inhaled b2-agonists (in
56.4%), inhaled ipratropium (in 62.8%), inhaled corticoster-
oids (in 20.5%), diuretics (in 53.9%), xanthines (in 6.4%) and
oral corticosteroids (in 9.0%). Comparison between survivors
and non-survivors revealed that, among the patients who
eventually died, PaO2 values were lower, SpO2 values were
lower, dyspnea sensation was greater (Figure 1), and SGRQ
impact scores were higher, as were SGRQ total scores.Follow up and mortality
By the end of the 1-year follow-up period, 12 patients
(15.4%) had died. The Kaplan–Meier analysis showed that BDI
p3 was the only categorical variable associated with higher
mortality (p ¼ 0.03) (Figure 2).
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Table 1 Baseline characteristic of the 78 COPD patients on LTOT according to the survival after 1-year follow-up.
Overall (n ¼ 78) Survivors (n ¼ 66) Non-survivors (n ¼ 12) p Value
Age (years) 66.078.9 65.679.1 68.277.9 0.37
Smoking (pack-years) 51.9741.9 51.3744.6 54.8724.3 0.39
FVC (% pred) 68.8717.5 70.4717.8 60.4712.7 0.07
FEV1 (% pred) 40.7716.1 41.7716.8 35.4710.9 0.22
FEV1/FVC (%) 47.0711.2 47.1711.1 46.6712.3 0.89
PaO2 (kPa) 7.071.5 7.171.4 6.171.5 0.03
PaCO2 (kPa) 6.471.3 6.271.0 7.072.2 0.37
SpO2 (%) 83.578.3 85.076.8 75.7711.4 0.004
Hemoglobin (g/dL) 15.172.6 15.272.7 14.972.5 0.79
Hematocrit (%) 48.278.8 48.278.9 48.277.7 0.99
BMI (kg/m2) 24.976.7 25.176.9 23.775.2 0.51
FFMI (kg/m2) 15.973.1 16.173.2 15.172.4 0.35
FFM (%) 68.679.3 68.579.6 69.277.8 0.98
FM (%) 31.078.5 31.078.7 30.877.8 1.00
HGS (kgf) 26.8710.1 27.5710.2 23.079.3 0.24
CCI 4.071.8 3.971.6 4.572.5 0.62
BDI 3.472.6 3.872.5 1.171.6 o0.001
SGRQ
Symptoms (%) 69.0722.4 66.9723.4 80.979.7 0.07
Activities (%) 74.7715.4 73.5715.8 81.2711.6 0.11
Impact (%) 50.1718.6 47.9718.8 62.6711.8 0.01
Total (%) 60.7716.1 58.8716.3 71.3710.0 0.01
Data are presented as mean7SD. The statistical tests used were the unpaired t-test or the Mann–Whitney test. FVC, forced vital
capacity; % pred, % of predicted; FEV1, forced expiratory volume in 1 s; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide
tension; SpO2, peripheral oxygen saturation; BMI, body mass index; FFMI, fat-free mass index; FFM, fat-free mass; FM, fat mass; HGS,
handgrip strength; kgf, kilogram-force CCI, Charlson comorbidity index; BDI, baseline dyspnea index; SGRQ, St. George’s Respiratory
Questionnaire.
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Figure 1 Distribution of baseline dyspnea index (BDI) at
baseline according to the survival after 1-year follow-up. The
boxes with bars give the percentiles 5%, 25%, 50% (median), 75%
and 95% of BDI for patients in the study.
First-year survival in COPD 515In the univariate Cox proportional hazards model, lower
PaO2, lower SpO2, higher PaCO2, higher SGRQ impact score
and higher SGRQ total score were associated with reduced
survival (Table 2). Variables presenting a po0.20 in the
univariate analysis (FVC, PaO2, PaCO2, SpO2, HGS and SGRQ
scores) were included in the multivariate Cox proportionalhazards models. In the multivariate analysis, BDI remained
predictive of mortality after adjusting for all other variables
included in the model (hazard ratio [HR], 0.50; 95%
conﬁdence interval [CI], 0.31–0.81; p ¼ 0.005), as did
PaO2 (HR, 0.49; 95% CI, 0.26–0.95; p ¼ 0.04) (Table 3).Discussion
In this study, we found that greater dyspnea and accentu-
ated hypoxemia were predictive of ﬁrst-year mortality in a
cohort of patients with very severe COPD and receiving
LTOT. To our knowledge, this is the ﬁrst study in which
dyspnea sensation was included in the analysis of predictive
factors for short-term survival in severe COPD patients
under LTOT. Our results suggest that dyspnea sensation,
which is a highly signiﬁcant symptom from the patient
perspective, is a valid indicator of ﬁrst-year survival.
The cut-off point for BDI was deﬁned as p3, a value
associated with severe functional impairment and dyspnea
upon mild exertion.25 In the present study, BDI values
associated with higher mortality were presented by 92% of
the non-survivors and by only 8% of the survivors. This cut-
off point for BDI showed a sensibility of 92% and speciﬁcity of
55% to predict mortality. In addition, its negative predictive
value was 97% and the positive predictive value was of 25%.
To our knowledge, only one study identiﬁed the modiﬁed
Medical Research Council dyspnea scale as a predictor
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Figure 2 Survival curves for patients with BDIp3 versus those with BDI43, (p ¼ 0.03). Kaplan–Meier survival curves for COPD
patients under LTOT.
Table 2 Results of the univariate mortality model
analysis in 78 patients with very severe COPD.
Variable Hazard ratio (95% CI) p Value
Smoking (pack-years) 1.00 (0.99–1.01) 0.85
FVC (% pred) 0.97 (0.93–1.00) 0.07
FEV1 (% pred) 0.97 (0.93–1.02) 0.21
FEV1/FVC (%) 1.00 (0.95–1.05) 0.84
PaO2 (kPa) 0.56 (0.35–0.91) 0.02
PaCO2 (kPa) 1.57 (1.10–2.23) 0.01
SpO2 (%) 0.91 (0.86–0.96) 0.0004
Hemoglobin (g/dL) 0.98 (0.78–1.22) 0.82
Hematocrit (%) 1.00 (0.94–1.07) 0.95
FFM (%) 1.01 (0.94–1.08) 0.85
FM (%) 1.00 (0.93–1.07) 0.94
HGS (kgf) 0.95 (0.90–1.01) 0.13
CCI 1.19 (0.89–1.61) 0.25
SGRQ
Symptoms (%) 1.03 (1.00–1.07) 0.06
Activities (%) 1.04 (0.99–1.08) 0.12
Impact (%) 1.04 (1.01–1.08) 0.02
Total (%) 1.06 (1.01–1.11) 0.02
CI, conﬁdence interval; FVC, forced vital capacity; % pred, %
of predicted; FEV1, forced expiratory volume in 1 s; PaO2,
arterial oxygen tension; PaCO2, arterial carbon dioxide
tension; SpO2, peripheral oxygen saturation; FFM, fat-free
mass; FM, fat mass; HGS, handgrip strength; kgf, kilogram-
force CCI, Charlson comorbidity index; SGRQ, St. George’s
Respiratory Questionnaire.
Table 3 Prognostic factors according to the multi-
variate mortality model.
Predictors Hazard ratio (95% CI) p Value
FVC (% pred) 1.01 (0.97–1.05) 0.53
PaO2 (kPa) 0.49 (0.26–0.95) 0.04
PaCO2 (kPa) 1.26 (0.77–2.05) 0.37
HGS (kgf) 0.93 (0.86–1.01) 0.08
BDI 0.50 (0.31–0.81) 0.005
SGRQ total score (%) 0.99 (0.94–1.05) 0.82
CI, conﬁdence interval; FVC, forced vital capacity; PaO2,
arterial oxygen tension; PaCO2, arterial carbon dioxide
tension; HGS, handgrip strength; kgf, kilogram-force; BDI,
baseline dyspnea index; SGRQ, St. George’s Respiratory
Questionnaire; % pred, % of predicted.
K.D. Coleta et al.516variable for 1-year survival; however, in this study were
included COPD patients with a wide range of disease
severity.28 Relationship between dyspnea perception and
5-year survival was evaluated in other studies.29,30 Nishi-
mura et al.29 compared the effects that dyspnea sensation
and COPD stage, as evaluated by FEV1, had on the 5-year
survival rate of 227 COPD patients with a wide range of
airway obstruction without hypoxemia. The Cox propor-
tional hazards model revealed that the categorization of
patients according to the level of dyspnea was morediscriminative than disease stage to predict 5-year survival.
In addition, a recent study by Oga et al.30 showed that BDI
score was signiﬁcantly correlated with 5-year survival in
patients with moderate to very severe COPD. However,
1-year survival and the presence of chronic hypoxemia were
not stated in the manuscript.30
Studies have documented the prognostic value of hypox-
emia in predicting survival in COPD patients with and
without LTOT.8,16,31 In a group of 487 patients with COPD,
the prognosis was signiﬁcantly affected by the degree of
hypoxemia after exercise.31 In addition, a PaO2o8.7 kPa
(65mmHg) under oxygen administration was independently
associated with reduced survival in a study evaluating 270
severely hypoxemic COPD patients under LTOT.8 However, a
higher PaO2 positively affected the survival rate in a cohort
of 47 chronic hypercapnic COPD patients.16 The results of
our multivariate analysis support these ﬁndings, suggesting
that hypoxemia remains an important predictive factor for
mortality in advanced COPD, even among patients receiving
LTOT.
Although the univariate analysis data suggest that higher
PaCO2 was associated with mortality, this variable was not
identiﬁed as a predictive factor in the multivariate analysis.
Our data are in contrast with those of previous studies that
identiﬁed hypercapnia as a predictive factor for mortality in
ARTICLE IN PRESS
First-year survival in COPD 517COPD patients under LTOT.9,32 However, those were long-
term survival studies and did not include dyspnea sensation
as a possible predictive factor in their multivariate analyses.
Similarly, we found health status measurements (SGRQ
scores) to be predictive only in the univariate analysis, as
observed in a previous study involving a cohort of patients
with severe emphysema.11
Many investigators have suggested that FEV1 is inversely
associated with mortality in COPD patients.13–15 However,
FEV1 was not found to be a predictive factor in our cohort.
This discrepancy might be attributable to the fact that the
previous studies did not include dyspnea sensation in their
multivariate analyses. In fact, Nishimura et al.29 found a
weak correlation between FEV1 and survival, suggesting that
the degree of dyspnea had a more signiﬁcant effect on
survival than did disease severity, as determined based on
FEV1. The authors suggested that the strong correlation
between dyspnea and survival weakened the correlation
between airway obstruction and dyspnea.
Long-term studies (X3 years in duration) have shown that
nutritional depletion, reﬂected by low values of BMI or FFMI,
is an independent risk factor for mortality in COPD patients,
regardless of pulmonary function status.10,14,15,27,33 In our
sample, the prevalence of patients with BMIo20 kg/m2
(21.8%) was similar to the values reported by Chailleux
et al.14 and higher than those observed in a recent study in
which mortality was found to be higher among patients
with advanced COPD receiving LTOT and presenting a
BMIo25 kg/m2.10 However, our analysis based on the Cox
proportional hazards model did not identify BMI or FFMI as
predictors of short-term mortality. Again, a possible
explanation is that those studies did not evaluate dyspnea.
In addition, the factors that are predictive of ﬁrst-year
survival might be different than those that are predictive of
long-term survival.
Some potential limitations of the present study should be
considered when interpreting our ﬁndings. First, our study
had a limited number of participants who died during the
follow-up period although the mortality rate, 15.4% in 1
year, is similar to other studies in comparable patients,
ranging from 17.2% to 30%.7–10 Therefore, we acknowledge
the small size of our cohort and that our study may be
underpowered to detect all the signiﬁcant differences
between survivors and non-survivors and also to detect
relationships between the risk factors and mortality.
Secondly, the adherence to LTOT was obtained by self-
reporting and although smokers were ineligible for LTOT,
smoking history was not biochemically conﬁrmed. It is
therefore possible that confounding due to these factors
may have contributed to our results and suggests that larger
studies are needed to obtain additional information on the
risk factors for ﬁrst-year survival in very severe COPD.Conclusion
Even though the small series of patients in this study should
prevent us from drawing deﬁnitive conclusions, our results
suggest that the intensity of dyspnea at baseline is a
predictor factor for ﬁrst-year survival in patients with very
severe COPD treated with LTOT. Similarly, the severity of
hypoxemia at baseline proved to be a predictive factor formortality, regardless of airways obstruction severity. How-
ever, larger trials are needed to evaluate whether ther-
apeutics interventions to reduce dyspnea and measures to
improve compliance with LTOT can inﬂuence survival in
patients with advanced COPD.
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